

Joost Wauters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5259477/publications.pdf>

Version: 2024-02-01

103
papers

5,658
citations

117453

34
h-index

88477

70
g-index

108
all docs

108
docs citations

108
times ranked

6990
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology. <i>Clinical Microbiology and Infection</i> , 2022, 28, 580-587.	2.8	133
2	Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza. <i>JCI Insight</i> , 2022, 7, .	2.3	38
3	Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 53-62.	1.1	12
4	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 827-840.	1.8	13
5	The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis. <i>Intensive Care Medicine</i> , 2022, 48, 768-769.	3.9	2
6	Lung donation and SARS-CoV-2 transmission: Missed detection versus missed opportunity?. <i>Immunity, Inflammation and Disease</i> , 2022, 10, e603.	1.3	4
7	Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a Post Hoc Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0229821.	1.8	17
8	Transient Increase of Pre-existing Anti-IFN- γ Antibodies Induced by SARS-CoV-2 Infection. <i>Journal of Clinical Immunology</i> , 2022, 42, 742-745.	2.0	12
9	Absence of candidemia in critically ill patients with COVID-19 receiving selective digestive decontamination. <i>Intensive Care Medicine</i> , 2022, 48, 611-612.	3.9	5
10	Thromboprophylaxis in COVID-19: Weight and severity adjusted intensified dosing. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12683.	1.0	4
11	Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 1.	1.5	12
12	Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study. <i>Mycoses</i> , 2022, 65, 656-660.	1.8	3
13	Lung Aeration in COVID-19 Pneumonia by Ultrasonography and Computed Tomography. <i>Journal of Clinical Medicine</i> , 2022, 11, 2718.	1.0	3
14	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	3.3	110
15	Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	59
16	Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2479-2488.	1.3	6
17	Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. <i>British Journal of Haematology</i> , 2021, 192, 1100-1105.	1.2	51
18	Invasive Pulmonary Aspergillosis Goes Viral Again?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 275-277.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Endogenous IFN γ expression predicts outcome in critical patients with COVID-19. <i>Lancet Microbe</i> , The, 2021, 2, e235-e236.	3.4	7
20	Five-year outcome of respiratory muscle weakness at intensive care unit discharge: secondary analysis of a prospective cohort study. <i>Thorax</i> , 2021, 76, 561-567.	2.7	11
21	Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 362-371.	1.5	69
22	Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. <i>EBioMedicine</i> , 2021, 66, 103288.	2.7	21
23	Meropenem Stability in Human Plasma at $\sim 20^\circ\text{C}$: Detailed Assessment of Degradation. <i>Antibiotics</i> , 2021, 10, 449.	1.5	8
24	Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis. <i>Cell Reports Medicine</i> , 2021, 2, 100289.	3.3	15
25	Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study. <i>Antibiotics</i> , 2021, 10, 557.	1.5	9
26	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. <i>Intensive Care Medicine</i> , 2021, 47, 674-686.	3.9	49
27	Letter to the Editor regarding: Ceftriaxone exposure in patients undergoing extracorporeal membrane oxygenation. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106326.	1.1	4
28	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834.	3.9	106
29	Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis. <i>Microorganisms</i> , 2021, 9, 1310.	1.6	14
30	COVID-19-associated <i>Aspergillus</i> tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 795-802.	5.2	56
31	Diagnosis and treatment of COVID-19 associated pulmonary aspergillosis in critically ill patients: results from a European confederation of medical mycology registry. <i>Intensive Care Medicine</i> , 2021, 47, 1158-1160.	3.9	43
32	A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. <i>Microorganisms</i> , 2021, 9, 1543.	1.6	23
33	Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 653-663.	0.6	3
34	Inhaled liposomal amphotericin-B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis/aspergillus tracheobronchitis. <i>Critical Care</i> , 2021, 25, 298.	2.5	31
35	Autoantibodies neutralizing type I IFNs are present in $\sim 4\%$ of uninfected individuals over 70 years old and account for $\sim 20\%$ of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	5.6	357
36	Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, e78-e79.	5.2	30

#	ARTICLE	IF	CITATIONS
37	Aspergillus Test Profiles and Mortality in Critically Ill COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0122921.	1.8	50
38	Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid. <i>Antibiotics</i> , 2021, 10, 1112.	1.5	5
39	Interaction between flucloxacillin and azoles: is isavuconazole next?. <i>Mycoses</i> , 2021, 64, 1508-1511.	1.8	3
40	COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges. <i>Intensive Care Medicine</i> , 2021, 47, 1339-1340.	3.9	27
41	Early lung ultrasound assessment for the prognosis of patients hospitalized for COVID-19 pneumonia. A pilot study. <i>Respiratory Medicine and Research</i> , 2021, 80, 100832.	0.4	1
42	Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. <i>Cell Research</i> , 2021, 31, 272-290.	5.7	229
43	Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1234-1241.	1.3	14
44	Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019. <i>Clinical and Translational Immunology</i> , 2021, 10, e1271.	1.7	36
45	Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model. <i>Virulence</i> , 2021, 12, 2493-2508.	1.8	20
46	Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients. <i>Microorganisms</i> , 2021, 9, 2068.	1.6	8
47	Critical influenza and prophylactic antifungal therapy for aspergillosis: a nuanced approach to a pertinent infectious disease. <i>Intensive Care Medicine</i> , 2021, 47, 1343-1344.	3.9	0
48	Multinational Observational Cohort Study of COVID-19-associated Pulmonary Aspergillosis. <i>Emerging Infectious Diseases</i> , 2021, 27, 2892-2898.	2.0	82
49	Clinical practices underlie COVID-19 patient respiratory microbiome composition and its interactions with the host. <i>Nature Communications</i> , 2021, 12, 6243.	5.8	42
50	Ultra-performance liquid chromatography for quantification of amphotericin B plasma concentrations after use of liposomal amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 961-966.	1.3	2
51	Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. <i>Cell</i> , 2021, 184, 5932-5949.e15.	13.5	245
52	Aerobic exercise capacity in long-term survivors of critical illness: secondary analysis of the post-EPaNIC follow-up study. <i>Intensive Care Medicine</i> , 2021, 47, 1462-1471.	3.9	17
53	Influenza-Associated Pulmonary Aspergillosis: Seek, and You Shall Find!. <i>Critical Care Medicine</i> , 2021, 49, e1265-e1266.	0.4	3
54	A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA). <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 1067.	1.5	52

#	ARTICLE	IF	CITATIONS
55	Influenza Coinfection: Be(a)ware of Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 349-350.	2.9	20
56	Preoperative joint aspiration culture results and causative pathogens in total hip and knee prosthesis infections: mind the gap. <i>Acta Clinica Belgica</i> , 2020, 75, 284-292.	0.5	11
57	Influenza-Associated Pulmonary Aspergillosis: A Local or Global Lethal Combination?. <i>Clinical Infectious Diseases</i> , 2020, 71, 1764-1767.	2.9	37
58	Intensive care unit acquired muscle weakness in COVID-19 patients. <i>Intensive Care Medicine</i> , 2020, 46, 2083-2085.	3.9	93
59	Does Pulmonary Aspergillosis Complicate Coronavirus Disease 2019?. , 2020, 2, e0211.		10
60	Point of care aspergillus testing in intensive care patients. <i>Critical Care</i> , 2020, 24, 642.	2.5	20
61	Establishing a Unified COVID-19 "Immunome" Integrating Coronavirus Pathogenesis and Host Immunopathology. <i>Frontiers in Immunology</i> , 2020, 11, 1642.	2.2	11
62	Diagnosis of Invasive Aspergillosis in Intensive Care Unit Patients. <i>Current Fungal Infection Reports</i> , 2020, 14, 166-173.	0.9	2
63	Invasive Aspergillus Tracheobronchitis Emerging as a Highly Lethal Complication of Severe Influenza. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 646-648.	2.5	13
64	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020, 46, 1524-1535.	3.9	278
65	Can augmented renal clearance be detected using estimators of glomerular filtration rate?. <i>Critical Care</i> , 2020, 24, 359.	2.5	17
66	International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe. <i>Critical Care</i> , 2020, 24, 84.	2.5	27
67	Quantitative determination of colistin A/B and colistin methanesulfonate in biological samples using hydrophilic interaction chromatography tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2020, 12, 1183-1195.	1.6	13
68	Development and External Validation of an Online Clinical Prediction Model for Augmented Renal Clearance in Adult Mixed Critically Ill Patients: The Augmented Renal Clearance Predictor. <i>Critical Care Medicine</i> , 2020, 48, e1260-e1268.	0.4	14
69	Antifungal drugs: What brings the future?. <i>Medical Mycology</i> , 2019, 57, S328-S343.	0.3	141
70	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. <i>Critical Care</i> , 2019, 23, 219.	2.5	123
71	Aspergillosis related to severe influenza: A worldwide phenomenon?. <i>Clinical Respiratory Journal</i> , 2019, 13, 540-542.	0.6	10
72	Defining standards of CARE for invasive fungal diseases in the ICU. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii9-ii15.	1.3	10

#	ARTICLE	IF	CITATIONS
73	Cerebral cortex and respiratory muscles perfusion during spontaneous breathing attempts in ventilated patients and its relation to weaning outcomes: a protocol for a prospective observational study. <i>BMJ Open</i> , 2019, 9, e031072.	0.8	0
74	Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 562-570.	1.1	21
75	Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 471-480.	1.3	133
76	Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 782-792.	5.2	638
77	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. <i>Microbial Cell</i> , 2018, 5, 300-326.	1.4	81
78	Devastating cerebral Lipiodol® embolization related to therapeutic lymphangiography for refractory chylothorax in a patient with Behçet's disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 427-430.	0.6	5
79	In vitro evaluation of the hepatic disposition of colistin. <i>FASEB Journal</i> , 2018, 32, 693.10.	0.2	1
80	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. <i>Intensive Care Medicine</i> , 2017, 43, 509-518.	3.9	51
81	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. <i>Transplantation Direct</i> , 2017, 3, e156.	0.8	34
82	Software-guided versus nurse-directed blood glucose control in critically ill patients: the LOGIC-2 multicenter randomized controlled clinical trial. <i>Critical Care</i> , 2017, 21, 212.	2.5	50
83	Plasmalyte: No Longer a Culprit in Causing False-Positive Galactomannan Test Results. <i>Journal of Clinical Microbiology</i> , 2016, 54, 795-797.	1.8	15
84	Factors Impacting Unbound Vancomycin Concentrations in Different Patient Populations. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7073-7079.	1.4	33
85	Hyperammonemia, resolved by chemotherapy. <i>Annals of Hematology</i> , 2014, 93, 1429-1430.	0.8	0
86	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1072-1083.	2.9	843
87	Pharmacokinetic changes after placement of a transjugular intrahepatic portosystemic shunt. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 377-378.	0.8	3
88	Protein-Binding Characteristics of Voriconazole Determined by High-Throughput Equilibrium Dialysis. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 2565-2570.	1.6	32
89	Impact of Hypoalbuminemia on Voriconazole Pharmacokinetics in Critically Ill Adult Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6782-6789.	1.4	52
90	The influence of continuous venovenous renal replacement therapy on the plasma disappearance rate of indocyanine green. <i>Intensive Care Medicine</i> , 2013, 39, 2231-2232.	3.9	3

#	ARTICLE	IF	CITATIONS
91	Invasive pulmonary aspergillosis in the ICU: reply to Wichmann et al.. Intensive Care Medicine, 2013, 39, 791-791.	3.9	0
92	The Eagle-like effect of echinocandins: whatâ€™s in a name?. Expert Review of Anti-Infective Therapy, 2013, 11, 1179-1191.	2.0	24
93	Relationship between Abdominal Pressure, Pulmonary Compliance, and Cardiac Preload in a Porcine Model. Critical Care Research and Practice, 2012, 2012, 1-6.	0.4	35
94	A Novel Method (CiMON) for Continuous Intra-Abdominal Pressure Monitoring: Pilot Test in a Pig Model. Critical Care Research and Practice, 2012, 2012, 1-7.	0.4	12
95	Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Medicine, 2012, 38, 1761-1768.	3.9	220
96	Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Review of Gastroenterology and Hepatology, 2011, 5, 523-537.	1.4	80
97	Pharmacokinetics of Voriconazole During Continuous Venovenous Hemofiltration. Therapeutic Drug Monitoring, 2011, 33, 372.	1.0	0
98	Albumin dialysis: current practice and future options. Liver International, 2011, 31, 9-12.	1.9	21
99	Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology, 2011, 54, 1741-1752.	3.6	86
100	MOLECULAR ANALYSIS OF SEPSIS-INDUCED CHANGES IN THE LIVER. Shock, 2010, 34, 427-436.	1.0	11
101	The Impact of Resuscitated Fecal Peritonitis on the Expression of the Hepatic Bile Salt Transporters in a Porcine Model. Shock, 2010, 34, 508-516.	1.0	8
102	The Effect of Strict Blood Glucose Control on Biliary Sludge and Cholestasis in Critically Ill Patients. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2345-2352.	1.8	53
103	Pathophysiology of Renal Hemodynamics and Renal Cortical Microcirculation in a Porcine Model of Elevated Intra-abdominal Pressure. Journal of Trauma, 2009, 66, 713-719.	2.3	56